MoonLake Immunotherapeutics - Ordinary Shares - Class A
MLTX
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.5B
Close$
$4.01
79.4% downside
Current Fair Value
79.4% downsideOvervalued by 79.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.50 Billion |
|---|---|
| Enterprise Value | $1.30 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.53 |
| Beta | 1.04 |
| Outstanding Shares | 71,273,650 |
Return
| Return on Equity | -101.49% |
|---|---|
| Return on Assets | -64.39% |
| Return on Invested Capital | -52.14% |
Valuation & Multiples
| P/E Ratio | -5.25 |
|---|---|
| PEG | -7.17 |
| Price to Sales | - |
| Price to Book Ratio | 6.51 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -7.04 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | 0.4 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 11, 2026
EPS Estimate
$-0.91
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 4, 2026
EPS Estimate
$-0.91
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 24.99% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.26%▼ 97.55% |
|---|---|
| Total Invested | $3.57M▼ 99.70% |
| Investors Holding | 3▼ 156.00% |
ESG Score
No data